Curapel is a privately held, natural products skincare company based in South Wales that spun out of the world-renowned Dermatology Centre of the University of Manchester in 2014.  It is developing innovative, safe and effective technologies to combat the common and distressing skin conditions psoriasis and eczema as well as various cosmetic applications.

Curapel has already demonstrated initial, pre-clinical efficacy and is validating further its patented portfolio of products based on naturally occurring actives which were identified using extensive skin biology and clinical dermatology expertise. Curapel is launching a series of safe and efficacious skincare products onto the market which will be available initially via e-commerce and latterly via high street retailers.  Curapel’s product actives, unlike mainstream pharmaceutical treatments, are naturally occurring and have been designated as Generally Regarded As Safe (GRAS) by the FDA.

Curapel’s proven initial efficacy, IP protection across the portfolio and GRAS active status is an unusual and commercially compelling combination.